

Cytecure Hospitals
Venkatala, Near Bagalur Cross
Yelahanka, Bengaluru 560 064
Ph: 1800 123 6767
Email: enquiry@cytecure.com

www.cytecure.com



FIGHTING CANCER
THE RIGHT WAY



BOARD MEMBERS & ADVISORS



Ravi Achar
Board Member. CEO, Arnold A Semler Inc (AAS). Co-Founder & Managing Director, Semler Research Center (SRC). Ex Board Member, Innopharma. Board Member, Ocugen. Advisory Member, TesoRx, Genzum Life Sciences, Generico, and Nova Therapeutics.Over 30 years in Operations, Business Development, Management, Strategic Alliances, Finance and International Business. Global entrepreneur worked in over 60 countries, establishing business for AAS, in Europe, Asia, South America, Middle East and Africa. Bachelors of Mechanical and Electronics Engineering, RV College, Bangalore. MBA, Pace University, New York.



Shikhar Dharamsey
Board Member. Overall management of Bipin Dharamsey LLC, business development and investments. Board member, AI Omaniya Financial Services, SAOG, Samatel Telecommunications, SAOC, AI Maha Financial Services LLC. BBA, Babson College, USA. MBA, Indian Institute of Management, Kolkata.



Vishal Bali
Board Member. Co-founder & Chairman, Medwell Ventures Pvt. Ltd. Asia Head- Healthcare, TPG Growth. Over 24 years of experience building global healthcare delivery organisations in developed and developing countries through organic and M&A driven growth initiatives. Managed an integrated healthcare delivery system comprising hospitals, diagnostics, primary care and daycare speciality. Invited member of the Strategic Initiatives Group of Joint Commission International, US, and a past member of the Global Agenda Healthcare Council of the World Economic Forum.



Akila Krishnakumar
Advisor. Co-founder and CEO, HealthAge Ventures. Chairperson, Social Venture Partners, Bangalore. Advisor, Medwell Ventures. Former President & Country Head, SunGard India. Over 30 years of leading businesses ranging from 15mn-500mn USD. Chairperson for the American Chamber of Commerce in India and NASSCOM Regional Council. Speaker at International Conferences. Receptient of several awards, including 'Top 5 women leaders in the Indian technology industry', and '50 Most Powerful Business Women in India'. Alumnus of BITS, Pilani.



Dr. Naren Ramakrishnan, MD PhD
Advisor. Director of Proton therapy, Neurologic and Paediatric Radiation Oncology, & Co-Director of the Brain and Spine Tumour Programme at the University of Florida Health Cancer Center, Orlando Health. Director, Proton Therapy, UF Health Cancer Center. Instructor, Radiation Oncology, Harvard Medical School. Former Chief, Central Nervous System Radiation Oncology, Dana-Farber Cancer Institute/Brigham and Women's Hospital. Professor, Radiation Oncology, University Of Central Florida College of Medicine. Diplomate, United States Medical licensing examination and the American Board of Radiology. Member of ASCO, ASTRO, and AACR.

NO TWO CANCER PATIENTS ARE THE SAME. NO TWO TREATMENTS ARE THE SAME.

Personalised cancer care stems from the insight that no two cancer patients are ever the same, and that no two treatments work in exactly the same way. Personalised cancer care can greatly improve treatment outcomes through a deeper understanding of each patient. It applies every ounce of knowledge gained from the patient’s personal medical history, genetics, physiology and tumour biology, to pinpoint, track and aggressively fight the cancer.

Personalised cancer care applies to all aspects of care, clinical and emotional, and through the patient’s entire journey from diagnosis to treatment, and even after discharge.



.....

CYTECARE FOUNDERS

Cytecare is led by a group of like-minded professionals, highly experienced in leading healthcare, research and life sciences businesses globally. They were brought together by a common cause, to provide high quality cancer care. Recognising the significant dearth of research data and the use of standard, evidence-based protocols in cancer therapy in India, they saw the opportunity to bring in global best practices that focused on individual patient needs and aimed at better clinical outcomes.

.....



BOARD MEMBERS & ADVISORS



Dr. A S Arvind, MD, FRCP
Board Member. Advisor, Milann, Ecron Acunova & Quark Pharmaceuticals. COO, Clinigene Intl. Ltd. Consultant Physician at West Wales General Hospital, UK. Medical Director of Mallya Hospital, Bangalore. Assistant Professor in Gastroenterology at St. John's Medical College, Bangalore. Research Fellow & Hon. Senior Registrar at St. Bartholomew's Hospital & St. Mark's Hospital, London. Registrar at Broadgreen Hospital, Liverpool, UK. Alumnus of St. John's Bangalore. MD, Bangalore Medical College. FRCP, London and Glasgow, UK. MBA, University of Birmingham, UK.



Dr. Gerardus Hoogland, MD, MBA
Board Member. CEO at HealthCrest AG, Switzerland. Over 30 years of experience in pharma, healthcare and research businesses. Was CEO, Schering, New Zealand and South Africa. Founder of Pharmaplan Pty. Ltd. that got acquired by Litha Healthcare Group. Board Member at the CBMG (China Bio Med Group listed on Nasdaq OTC), and Allcare AG (a Zurich-based primary care group practice). Graduated as a Doctor from the Amsterdam University. Studied law at the Erasmus University, Holland. MBA from INSEAD, France.



Gillian Corken, MPharm (cum laude)
Board Member. Chairperson, Triclinium Clinical Development Pty Ltd. Board Member, Cytespace Research Pvt Ltd. Board Member, Medwell Ventures Pvt Ltd. Built successful healthcare ventures in developing markets. Co-founder, Clindepharm International Pty. Ltd., which was acquired by the US-based Quintiles Transnational Inc. Senior positions at Quintiles in the US and Brazil. Board member across Asia, Africa and Europe. Member of the International Community for Accordia, and natural therapy companies, Phytotherapy Pty. Ltd. and Phytoderm cc.



John Goodacre
Board Member. Senior executive roles at Quintiles Transnational Holdings Inc. and its predecessor companies, from 1998 to 2015. Vice President and Head, European Legal Affairs. Senior Vice President, Global Risk Management and Quality Assurance. Executive Vice President and Senior Deputy General Counsel. Executive Vice President, General Counsel and Corporate Secretary. Worked as a lawyer and partner in various law firms in London. Admitted as a Solicitor in England and Wales. MA in law from Cambridge University, UK.



Dr. Oppel Greeff, MD
Board Member, Triclinium Clinical Development Pty Ltd. Board Member, Cytespace Research Pvt Ltd. Board Member, Medwell Ventures Pvt Ltd. Professor of Pharmacology, University of Pretoria. Ex-President & CEO of Africa, Asia and Australia (AAA) Quintiles Transnational. Ex-Vice Chairman of Quintiles Transnational. Chairman of Cenduit, LLC. Director of Aspen Pharmacare Holdings Ltd. Co-founded PharmaNet Inc., a retail pharmacy franchise. M.D. In Psychiatry from the University of Natal. MpharmMed and MBChB, University of Pretoria. Fellow of the Faculty of Pharmaceutical Medicine, the Royal Colleges of Physicians, UK.

EXECUTIVE LEADERSHIP



Ferzaan Engineer, PhD | Co-founder & Chairman
Board Member. Co-founder & Chairman, Cytespace Research Pvt. Ltd. Co-founder & Co-Chairman, Medwell Ventures Pvt. Ltd. Scientific Advisor to Cellworks, USA and Image Core Lab, India. Mentor at Escape Velocity Accelerator. Ex-CEO Quintiles India and Member, Asia-Pacific Management Board. Ex-Board Member at Cenduit LLC. PhD in Pharmaceutical Sciences, University of South Carolina, USA. Member of many professional bodies including a pharma committee advising the Government of India. Published various scientific papers, and lectured at Cambridge, IIMA and other universities.



Suresh Ramu | Co-founder & CEO
Board Member. Director, Cytespace Research Pvt. Ltd. Over 17 years of work experience. Lead, Quintiles India's Clinical Development. Asia-Pac Head of Global Data Management. Head of Operations for the Cardiac Safety business. Stint as Consultant at PricewaterhouseCoopers and part of telemedicine start-up. Engineering degree from IIT Madras and MBA from IIM Calcutta. Member of various professional bodies and speaker in international fora.



Himanshu Shah | Co-founder & CFO
Board Member. Co-founder & CFO, Cytespace Research Pvt. Ltd. Co-founder & CFO, Medwell Ventures Pvt. Ltd. Over 25 years of experience in the pharmaceutical and research industry. Board Member, Quintiles India. Strong experience in finance and governance functions. Alumnus of Kellogg School of Management, USA; IIM Ahmedabad and ISB, India.



Dr. Anthony Pais, MS | Co-founder & Clinical Director
Senior Consultant - Oncoplastic Breast Surgery. Over 28 years of experience in surgical oncology. Specially trained in Breast Ultrasound and interpreting mammograms in Japan and USA. Practiced extensively in surgical oncology across Mazumdar Shaw Cancer Center, Narayana Hrudayalaya Multispecialty Hospital, Tata Memorial Hospital, Mumbai, and KIDWAI Memorial Institute of Oncology, Bangalore. Active member of Breast Surgery International, Switzerland, the American Society of Breast diseases and International Society of Surgeons.



Dr. Selwyn Colaco | Chief Operating Officer
Physician Manager and empanelled NABH assessor. Over 25 years of clinical and management experience in various healthcare systems. Experience with hospital chains including Apollo, Fortis, BGS Global Hospitals, Manipal Hospital and Narayana Health. MBBS; MHA from Administrative Staff College of India (a programme in association with Johns Hopkins University).



"Cytecare is building Centers of Clinical Excellence across India and will introduce best practices through our growing hospital network."

**- Ferzaan Engineer, PhD
Co-founder and Chairman**



CYTECARE SPECIALITIES

Head and Neck Oncology | Breast Oncology
Gastrointestinal and Hepato-biliary Oncology
Gynaec Oncology | Medical Oncology
Haemato-Oncology | Radiation Oncology
Nuclear Medicine | Interventional Oncology
Pain and Palliative Care

TREATMENT TYPES

Chemotherapy
Surgery
- Reconstructive Surgery
- Minimally invasive Surgery
Radiation Therapy
Bone Marrow/ Stem Cell Transplant
Palliation

COMPREHENSIVE FACILITIES

150 Beds | Nuclear Medicine Suite (with PET CT)
Modular OTs | In-house Laboratory | In-house Blood Bank
Nutrition Services | Speech & Swallowing Rehabilitation
Clinic | Physiotherapy Services | Counselling
Differentiated ICUs into SICU (Surgical) and MICU
(Medical) | Variety of patient suites such as the Tranquil
Deluxe, Serene Premium Private, Zen Semi-Private
and Harmony Multi-Bed

“Cytecare aims to revolutionise cancer care by delivering personalised cancer treatment through an organ-site focus, clinical precision, patient-centric culture and a strong emphasis on research. These core principles are embedded within a strong clinical governance structure”

- Suresh Ramu
Co-founder and CEO

MEDICAL ONCOLOGY

Our medical oncologists design plans specific to the needs of each patient and use a combination of superior treatment options such as immunotherapy, hormone therapy, targeted therapy and chemotherapy.



SURGERY

Our surgeons are super-specialised in specific cancers pertaining to a specific organ or region of the body. This has become the standard of care in international cancer institutions, and Cytecure intends to bring this level of clinical quality to India.



RADIATION ONCOLOGY

Based on patient needs, our skilled radiation oncologists customise radiotherapy to meet specific requirements and deliver sophisticated therapies to a specific location in the body with great accuracy and speed.



ORGAN SITE FOCUS



Each type of cancer affects different organs in completely different ways. This can be attributed to a unique combination of genetics, environment, lifestyle, certain pre-existing conditions and other factors. Hence, it is crucial to have highly specialised knowledge about how an organ is affected by cancer.

At Cytecure, we have invested tremendously in organ-site focused systems and practices. Our super-specialised oncologists are trained and experienced in each particular organ site, be it head and neck or breast cancer. Their extensive knowledge of each organ site enables them to detect and diagnose cancers more accurately, and also much faster. The precision achieved through organ-site focus can greatly improve treatment outcomes for cancer patients, as proven by statistics from across the world.

"Cancer is divided into many organ sites and each of these have to be treated by specialists in that organ site. This dramatically improves outcomes for the patient."

- Dr. Anthony Pais
Co-founder and Clinical Director
Senior Oncoplastic Breast Surgeon

DIGITAL MAMMOGRAPHY & TOMOSYNTHESIS (DMT)

Digital Breast Tomosynthesis (DBT) is the next generation in breast imaging digital technology. At Cytecure, we have a digital mammogram with tomosynthesis, which is the first of its kind in Karnataka. Doctors have a plethora of viewing and analysing options at their disposal, including better clarity, zoom, and the ability to highlight certain areas and electronically transmit images.




RADIATION THERAPY

Cytecure is the first hospital in the state of Karnataka to have the Elekta Versa HD. This ground-breaking linear accelerator is used in the delivery of stereotactic body radiotherapy (SBRT) and radiosurgery (SRS) programmes, worldwide. The VERSA HD was designed with patient safety in mind along with higher precision, and provides the industry's largest IGRT cone-beam CT field-of-view.



ADVANCED EQUIPMENT



Technology in the field of cancer has been evolving at a rapid pace. To ensure that our clinical team has the best-in-class technology to deliver high quality care, Cytecure has invested in advanced diagnostic and therapeutic modalities.

DIAGNOSTIC IMAGING

The latest diagnostic technology together with skilled clinical and technical expertise are necessary for early and accurate detection of cancer. This is critical for determining the way forward with respect to treatment and therapy. Cytecure offers a variety of diagnostic tests depending on the specific patient and cancer type, including:

- Nuclear Medicine (PET CT, Bone scans, etc.)
- Radiology (Digital Mammography, Ultrasound, X-Ray)
- Pathology
- Biopsy
- Endoscopy



PET CT

Cytecure has a state-of-the art PET CT - the GE Discovery IQ 16 slice PET with LightBurst technology which reduces scan time and provides improved scan quality. The system has Q Clear technology to reconstruct images to improve SUV without compromising on image quality, as well as motion correction in order to enable better lesion detection.

SPECIALIST ONCOLOGISTS



Treating a disease as complex as cancer requires a high degree of specialisation. More so, when it comes to the organ-site focused treatment followed at Cytecure, which involves the intricate understanding of different cancers with respect to different organs in the body. Cytecure's dedicated

team of oncology experts are all super-specialised in the cancer of a particular organ. They include renowned medical oncologists, surgical oncologists, radiation oncologists and other experts.

STANDARDISED GLOBAL GUIDELINES



At Cytecure, we have set ourselves the highest of standards, based on and drawn from globally recognised gold standard guidelines, such as the National Comprehensive Cancer Network (NCCN), European Society for Medical Oncology (ESMO), National Health Service (NHS), Indian Council of Medical Research (ICMR) and Tata Memorial Hospital.

These guidelines standardise care pathways for patients and offer a number of knowledge programmes to clinicians that can help guide decision-making in the management of cancer. We aim to harmonize and apply these evidence-based guidelines to suit Indian demographics, so as to improve outcomes.



EMOTIONAL SUPPORT AND PATIENT WELL-BEING

Cytecure imbibes a holistic care approach which is cognizant of and responsive to individual patient needs and values, both at a physiological and emotional level. This is implemented through empathetic and compassionate interactions between all clinicians and patients. The emotional aspect of care, which is often overlooked, will be addressed through a sound, professional counselling programme which will be offered to all our patients and their families/caregivers through the entire course of the treatment.

TUMOUR BOARD



The right governance of care is crucial to balance the tenets of organ-site focus and guideline standards. Bearing this in mind, Cytecure has established a Tumour Board - a team of specialised doctors who bring their individual expertise into determining the most effective treatment path. Our Tumour Board will include Medical and/or Surgical Oncologists, Radiation Oncologists, Pathologists and Radiologists, along with other specialists, to evaluate and decide the best treatment approach and track the progress of each patient's condition. We also seek recommendations from specialists across the world via video conferencing,

so as to access the best clinical opinions, which undergo a rigorous review before being implemented.

"At Cytecure, you don't get just one doctor, but a team working together. Our multi-disciplinary panel of specialists meet every week to review cases and reach a consensus on the best course of treatment for every patient."

- Dr. Selwyn Colaco
Chief Operating Officer

RESEARCH



Cancer care is a constantly evolving discipline. Research is necessary from a patient perspective as it offers them an opportunity to participate in the latest global research studies. Cytecure is highly focused on clinical research to ensure consistently better clinical outcomes. Our doctors are research-oriented, seeking evidence-based protocol methods, while continuously updating themselves about the latest advancements.

Cytecure also aims to develop collaborations with top global research institutions. Through these initiatives, we will use information for continuous improvement in our data-driven, evidence based and scientific approach to treating our patients.